James E. Barrett

Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA.

Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ.

Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ.

Part of Pfizer Inc., Lederle Laboratories is a company that provides testing services. The company is based in Pearl River, NY.

The Federation of American Societies for Experimental Biology (FASEB) is a non-profit organization that represents over 130,000 scientists and researchers in the field of biological and biomedical sciences. The private company is based in Bethesda, MD. FASEB aims to advance health and welfare by promoting progress and education in these fields. The organization provides a platform for collaboration and communication among scientists, as well as advocating for funding and policies that support scientific research.

AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD.